Analysis of the risk factors for severity in post endoscopic retrograde cholangiopancreatography pancreatitis: The indication of prophylactic treatments

Table 2 Clinical data and endoscopic retrograde cholangiopancreatography intervention of patients with post endoscopic retrograde cholangiopancreatography pancreatitis

Variables	Mild-moderate PEP (n = 107)	Severe PEP (n = 14)
ERCP procedure
Not emergency/emergency	91/16	13/1
EST	29	2
EPBD	12	2
Pancreatography
No/yes	38/69	9/5
Contrast media remained in the pancreatic duct
No/yes	75/32	5/9
IDUS
No/yes	86/21	9/5
Transpapillary biopsies
No/yes	76/31	10/4
Time for ERCP procedure (min)
Median	50	56
(range)	(12-170)	(26-150)
Expertise of ERCP procedure
Not expert/expert	62/45	9/5
Abdominal pain within three hours after ERCP
No/yes	49/58	1/13
Serum amylase level of the next day (IU/mL)
Median	1001	1543
(range)	(83-3604)	(258-2969)
White blood cell of the next day (/μL)
median	8040	8790
(range)	(3240-26320)	(6270-13410)
C-reactive protein of the next day (mg/dL)
Median	2.08	3.1
(range)	(0.04-32.55)	(0.20-38.31)

ERCP: Endoscopic retrograde cholangiopancreatography; PEP: Post endoscopic retrograde cholangiopancreatography pancreatitis; EST: Endoscopic sphincterotomy; EPBD: Endoscopic papillary balloon dilation; IDUS: Intraductal ultrasonography.